CPhI Online

- Market News

Vetter opens Chinese office to support promising injectable pipeline

8 Mar 2021

The strategic move will enable the injectables CDMO to support domestic companies that plan on bringing their molecules to the global market

CDMO Vetter, which specialises in prefilled drug-delivery systems, has opened a new office in Shanghai, China to strengthen its footprint in the Asia Pacific region.

The new office, located in Puxi, Shanghai, is strategically positioned on Nanjing Road West in the heart of the city’s Central Business District.

The office, which opened on March 8, is Vetter's fourth in the region; it also has an Asia Pacific (APAC) regional office in Singapore, as well as sales offices in Japan and South Korea.

“With an increased share of Asian firms among the Top 50 Pharma companies worldwide over the last several years, our mission is to service the needs of our global customer base, of course including Asia, in the best-possible way," said Vetter CEO Peter Sölkner.

In a statement, Vetter said that as the second-largest pharmaceutical market and one of the largest in sales growth rate worldwide, China offers a promising injectable pipeline and allows the company to offer support to domestic companies that plan on bringing their molecules to the global market.

Vetter offers services to customers through every phase of their injectable drug product’s lifecycle, from early development activities to commercial supply up to lifecycle initiatives.

The office is staffed by Mr Jason Zhong, who assumes the position of Business Development Manager China. As the first member of the new team in China, Mr Zhong will lead Vetter’s business activities reporting to Ms Chervee Ho, who is Vetter’s Director Key Account Management Asia Pacific, based in Singapore.

Read More

Related Content